Qinzhen Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qinzhen Cheng has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoyuan Ji
Academy of Medical Engineering and Translational Medicine Medical College Tianjin University Tianjin China
2 shared publications - Lingling Xu
School of Nanoscience and Engineering University of Chinese Academy of Sciences Beijing China
1 shared publication Shuquan Zhang
Department of Orthopedics Integrated Chinese and Western Medicine Hospital Tianjin University Tianjin China
1 shared publicationYalan Zhu
Department of Pharmacy, Jinhua Municipal Central Hospital, Jinhua, Zhejiang, 321000, China
1 shared publication- Yalan Zhu
Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, People’s Republic of China
1 shared publication Yaoguang She
Department of General Surgery First Medical Center Chinese People's Liberation Army (PLA) General Hospital Beijing China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 21 March 2024
- Published by Wiley in Exploration
- Vol. 4 (6) , 20230164
Innovative utilization of cell membrane‐coated nanoparticles in precision cancer therapy
Cell membrane‐coated nanoparticles (CMNPs) have recently emerged as a promising platform for cancer therapy. By encapsulating therapeutic agents within a cell membrane‐derived coating, these nanoparticles combine the advantages of synthetic nanoparticles and natural cell membranes. This review provides a comprehensive overview of the recent advancements in utilizing CMNPs as effective drug delivery vehicles for cancer therapy. The synthesis and fabrication methods of CMNPs are comprehensively discussed. Various techniques, such as extrusion, sonication, and self‐assembly, are employed to coat synthetic nanoparticles with cell membranes derived from different cell types. The cell membrane coating enables biocompatibility, reducing the risk of an immune response and enhancing the stability of the nanoparticles in the bloodstream. Moreover, functionalization strategies for CMNPs, primarily chemical modification, genetic engineering, and external stimuli, are highlighted. The presence of specific cell surface markers on the coated membrane allows targeted drug delivery to cancer cells and maximizes therapeutic efficacy. Preclinical studies utilizing CMNPs for cancer therapy demonstrated the successful delivery of various therapeutic agents, such as chemotherapeutic drugs, nucleic acids, and immunotherapeutic agents, using CMNPs. Furthermore, the article explores the future directions and challenges of this technology while offering insights into its clinical potential.
- 21 March 2024
- Published by Wiley in Exploration
- Vol. 4 (6) , 20230164
Top Cited PapersOpen AccessInnovative utilization of cell membrane‐coated nanoparticles in precision cancer therapy
Cell membrane‐coated nanoparticles (CMNPs) have recently emerged as a promising platform for cancer therapy. By encapsulating therapeutic agents within a cell membrane‐derived coating, these nanoparticles combine the advantages of synthetic nanoparticles and natural cell membranes. This review provides a comprehensive overview of the recent advancements in utilizing CMNPs as effective drug delivery vehicles for cancer therapy. The synthesis and fabrication methods of CMNPs are comprehensively discussed. Various techniques, such as extrusion, sonication, and self‐assembly, are employed to coat synthetic nanoparticles with cell membranes derived from different cell types. The cell membrane coating enables biocompatibility, reducing the risk of an immune response and enhancing the stability of the nanoparticles in the bloodstream. Moreover, functionalization strategies for CMNPs, primarily chemical modification, genetic engineering, and external stimuli, are highlighted. The presence of specific cell surface markers on the coated membrane allows targeted drug delivery to cancer cells and maximizes therapeutic efficacy. Preclinical studies utilizing CMNPs for cancer therapy demonstrated the successful delivery of various therapeutic agents, such as chemotherapeutic drugs, nucleic acids, and immunotherapeutic agents, using CMNPs. Furthermore, the article explores the future directions and challenges of this technology while offering insights into its clinical potential.
- Top Cited Papers
- 20 January 2024
- Published by Elsevier in Biomaterials
- Vol. 306, 122478
Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond
- 20 January 2024
- Published by Elsevier in Biomaterials
- Vol. 306, 122478
Top Cited PapersPlatelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond